ESC 365 - PCSK9 inhibition: from biology to clinical applications.

ESC Premium Access

PCSK9 inhibition: from biology to clinical applications.

Session: Atherothrombosis: New Therapeutic Targets

Topic: Pharmacology and Pharmacotherapy, Other

Speaker: Professor G. Lambert (SAINT DENIS, RE)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Professor Gilles Lambert

INSERM, SAINT DENIS (Réunion)

3 presentations

0 follower

3 more presentations in this session

RNA-targeting therapeutics for lipid disorders.

Speaker: Professor S. Tsimikas (La Jolla, US)

Targeting new coagulation factors in atherothrombosis.

Speaker: Professor H. Ten Cate (Maastricht, NL)

The inflammasome: old drugs and new insights.

Speaker: Doctor J. Tardif (Montreal, CA)

Access the full session

Atherothrombosis: New Therapeutic Targets

Speakers: Professor G. Lambert, Professor S. Tsimikas, Professor H. Ten Cate, Doctor J. Tardif

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources